抄読会論文
-
-
-
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
- 2024.12.4 ｜ 抄読会論文
- 抄読会要旨 猿渡功一...
-
-
-
-
Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study
- 2024.07.10 ｜ 抄読会論文
- 抄読会要旨 今村光佑...
-
-
-
-
eClinical Medicine. 2024 Mar 22:70:102536. doi:10.1016/j.eclinm.2024.102536Title : Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective
- 2024.06.7 ｜ 抄読会論文
- 抄読会要旨 猪山慎治...
-
-
-
-
First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study Jpn J Clin Oncol. 2024 Apr 6;54(4):452-462.
- 2024.05.16 ｜ 抄読会論文
- 抄読会要旨 猿渡 功一...
-
-
-
-
Interstitial pneumonia with autoimmune features and histologic usual interstitial pneumonia treated with anti-fibrotic versus immunosuppressive therapy
- 2024.02.19 ｜ 抄読会論文
- 抄読会要旨 岡林比呂子...
-
-
-
-
Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer
- 2023.11.1 ｜ 抄読会論文
- 抄読会要旨 今村光佑...
-
-
-
-
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study
- 2023.10.27 ｜ 抄読会論文
- 抄読会要旨 猪山慎治...
-
-
-
-
High yield of pleural cell-free DNA for diagnosis of oncogenic mutations in lung adenocarcinoma
- 2023.10.12 ｜ 抄読会論文
- 抄読会要旨 木村俊貴...
-
-
-
-
Efzofitimod for the Treatment of Pulmonary Sarcoidosis
- 2023.09.21 ｜ 抄読会論文
- 抄読会要旨 岡林比呂子...
-
-
-
-
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer N Engl J Med. 2023 Jun 3. doi: 10.1056/NEJMoa2302983. Online ahead of print.
- 2023.07.4 ｜ 抄読会論文
- 抄読会要旨 猿渡功一...
-
